

Jun Pin Shi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2124111/publications.pdf>

Version: 2024-02-01

68
papers

2,152
citations

257450

24
h-index

254184

43
g-index

76
all docs

76
docs citations

76
times ranked

3344
citing authors

#	ARTICLE	IF	CITATIONS
1	The Accuracy and Clinical Relevance of the Multi-echo Dixon Technique for Evaluating Changes to Hepatic Steatosis in Patients with Non-alcoholic Fatty Liver Disease Treated with Formulated Food. <i>Magnetic Resonance in Medical Sciences</i> , 2023, 22, 263-271.	2.0	2
2	A novel radiomics signature based on T2-weighted imaging accurately predicts hepatic inflammation in individuals with biopsy-proven nonalcoholic fatty liver disease: a derivation and independent validation study. <i>Hepatobiliary Surgery and Nutrition</i> , 2022, 11, 212-226.	1.5	4
3	Association between nonalcoholic fatty liver disease and depression: A systematic review and meta-analysis of observational studies. <i>Journal of Affective Disorders</i> , 2022, 301, 8-13.	4.1	17
4	FMO4 shapes immunometabolic reconfiguration in hepatocellular carcinoma. <i>Clinical and Translational Medicine</i> , 2022, 12, e740.	4.0	3
5	Genome-wide meta-analysis identifies susceptibility loci for autoimmune hepatitis type 1. <i>Hepatology</i> , 2022, 76, 564-575.	7.3	11
6	The Mechanism Underlying the Influence of Indole-3-Propionic Acid: A Relevance to Metabolic Disorders. <i>Frontiers in Endocrinology</i> , 2022, 13, 841703.	3.5	26
7	The aberrant upregulation of exon 10-inclusive SREK1 through SRSF10 acts as an oncogenic driver in human hepatocellular carcinoma. <i>Nature Communications</i> , 2022, 13, 1363.	12.8	20
8	Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101876.	1.5	10
9	The Potential Role of Gut Microbial-Derived Exosomes in Metabolic-Associated Fatty Liver Disease: Implications for Treatment. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	7
10	Meta-analysis: global prevalence, trend and forecasting of non-alcoholic fatty liver disease in children and adolescents, 2000-2021. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 396-406.	3.7	28
11	Metabolic Disorders Combined with Noninvasive Tests to Screen Advanced Fibrosis in Nonalcoholic Fatty Liver Disease. <i>Journal of Clinical and Translational Hepatology</i> , 2021, 000, 000-000.	1.4	3
12	Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical and Translational Gastroenterology</i> , 2021, 12, e00323.	2.5	22
13	Health-related quality of life in Chinese population with non-alcoholic fatty liver disease: a national multicenter survey. <i>Health and Quality of Life Outcomes</i> , 2021, 19, 140.	2.4	15
14	Lactylation, a Novel Metabolic Reprogramming Code: Current Status and Prospects. <i>Frontiers in Immunology</i> , 2021, 12, 688910.	4.8	76
15	The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2021, 20, 426-432.	1.3	11
16	Alagille syndrome caused by NOTCH2 mutation presented atypical pathological changes. <i>Clinica Chimica Acta</i> , 2021, 521, 258-263.	1.1	6
17	Fecal Fungi Dysbiosis in Nonalcoholic Fatty Liver Disease. <i>Obesity</i> , 2021, 29, 350-358.	3.0	13
18	Comparing hepatic steatosis distribution patterns between non-alcoholic fatty liver disease and fatty liver disease with chronic hepatitis B by second-harmonic generation/two-photon excited fluorescence method. <i>Annals of Hepatology</i> , 2020, 19, 313-319.	1.5	7

#	ARTICLE	IF	CITATIONS
19	Nonalcoholic Fatty Liver Disease: Pathogenesis and Treatment in Traditional Chinese Medicine and Western Medicine. Evidence-based Complementary and Alternative Medicine, 2020, 2020, 1-16.	1.2	31
20	From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. Chinese Medical Journal, 2020, 133, 2271-2273.	2.3	79
21	SNGH16 regulates cell autophagy to promote Sorafenib Resistance through suppressing miR-23p via sponging EGR1 in hepatocellular carcinoma. Cancer Medicine, 2020, 9, 4324-4338.	2.8	28
22	Activation of HIF-1 signaling ameliorates liver steatosis in zebrafish atp7b deficiency (Wilson's disease) models. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2020, 1866, 165842.	3.8	14
23	TPGS-1000 exhibits potent anticancer activity for hepatocellular carcinoma in vitro and in vivo. Aging, 2020, 12, 1624-1642.	3.1	12
24	The Role of Intestinal Fungi and Its Metabolites in Chronic Liver Diseases. Gut and Liver, 2020, 14, 291-296.	2.9	7
25	Study on the new strategy and key techniques for accurate prevention and treatment of nonalcoholic steatohepatitis based on intestinal target bacteria. Medicine (United States), 2020, 99, e22867.	1.0	1
26	The p66shc-mediated Regulation of Hepatocyte Senescence Influences Hepatic Steatosis in Nonalcoholic Fatty Liver Disease. Medical Science Monitor, 2020, 26, e921887.	1.1	8
27	Identification and characterization of dynamically regulated hepatitis-related genes in a concanavalin A-induced liver injury model. Aging, 2020, 12, 23187-23199.	3.1	1
28	Wnt/ β -catenin signaling was activated in supporting cells during exposure of the zebrafish lateral line to cisplatin. Annals of Anatomy, 2019, 226, 48-56.	1.9	9
29	Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis. Obesity, 2019, 27, 2055-2066.	3.0	22
30	Knockout of neutrophil elastase protects against western diet induced nonalcoholic steatohepatitis in mice by regulating hepatic ceramides metabolism. Biochemical and Biophysical Research Communications, 2019, 518, 691-697.	2.1	30
31	Analysis of the <i>UGT1A1</i> Genotype in Hyperbilirubinemia Patients: Differences in Allele Frequency and Distribution. BioMed Research International, 2019, 2019, 1-9.	1.9	14
32	Ethanol extract of Ligustrum lucidum Ait. leaves suppressed hepatocellular carcinoma in vitro and in vivo. Cancer Cell International, 2019, 19, 246.	4.1	10
33	Haptoglobin 2-2 Genotype is Associated with More Advanced Disease in Subjects with Non-Alcoholic Steatohepatitis: A Retrospective Study. Advances in Therapy, 2019, 36, 880-895.	2.9	7
34	The association between nonalcoholic fatty liver disease and risk of colorectal adenoma and cancer incident and recurrence: a meta-analysis of observational studies. Expert Review of Gastroenterology and Hepatology, 2019, 13, 385-395.	3.0	29
35	Role of MicroRNAs in the Development of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Anatomical Record, 2019, 302, 193-200.	1.4	5
36	Discovering master regulators in hepatocellular carcinoma: one novel MR, SEC14L2 inhibits cancer cells. Aging, 2019, 11, 12375-12411.	3.1	15

#	ARTICLE	IF	CITATIONS
37	Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice. <i>American Journal of Translational Research (discontinued)</i> , 2019, 11, 2668-2682.	0.0	17
38	Haptoglobin Genotype and Vitamin E Versus Placebo for the Treatment of Nondiabetic Patients with Nonalcoholic Steatohepatitis in China: A Multicenter, Randomized, Placebo-Controlled Trial Design. <i>Advances in Therapy</i> , 2018, 35, 218-231.	2.9	13
39	Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase/hydrogen sulfide pathway. <i>Gut</i> , 2018, 67, 2169-2180.	12.1	114
40	Association of baseline vitamin D level with genetic determinants and virologic response in patients with chronic hepatitis B. <i>Hepatology Research</i> , 2018, 48, E213-E221.	3.4	19
41	Chronic moderate alcohol consumption relieves high-fat high-cholesterol diet-induced liver fibrosis in a rat model. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2018, 45, 1046-1055.	1.9	9
42	Prediction of hepatic necroinflammatory activity in patients with chronic hepatitis B by a simple noninvasive model. <i>Journal of Translational Medicine</i> , 2018, 16, 166.	4.4	5
43	Relationship of serum uric acid level with non-alcoholic fatty liver disease and its inflammation progression in non-obese adults. <i>Hepatology Research</i> , 2017, 47, E104-E112.	3.4	35
44	Potential Regulators Driving the Transition in Nonalcoholic Fatty Liver Disease: a Stage-Based View. <i>Cellular Physiology and Biochemistry</i> , 2017, 41, 239-251.	1.6	16
45	Characterization of transcriptional modules related to fibrosing-NAFLD progression. <i>Scientific Reports</i> , 2017, 7, 4748.	3.3	48
46	Berberine ameliorates non-alcoholic steatohepatitis in ApoE ^{-/-} mice. <i>Experimental and Therapeutic Medicine</i> , 2017, 14, 4134-4140.	1.8	23
47	Linarin Enriched Extract Attenuates Liver Injury and Inflammation Induced by High-Fat High-Cholesterol Diet in Rats. <i>Evidence-based Complementary and Alternative Medicine</i> , 2017, 2017, 1-9.	1.2	13
48	Abernethy malformation associated with Caroli's syndrome in a patient with a PKHD1 mutation: a case report. <i>Diagnostic Pathology</i> , 2017, 12, 61.	2.0	10
49	Evaluating the Relationship Between Metabolic Syndrome and Liver Biopsy-Proven Non-Alcoholic Steatohepatitis in China: A Multicenter Cross-Sectional Study Design. <i>Advances in Therapy</i> , 2016, 33, 2069-2081.	2.9	13
50	AKT/mTOR signaling pathway is involved in salvianolic acid B-induced autophagy and apoptosis in hepatocellular carcinoma cells. <i>International Journal of Oncology</i> , 2016, 49, 2538-2548.	3.3	48
51	Lipocalin-2 mediates non-alcoholic steatohepatitis by promoting neutrophil-macrophage crosstalk via the induction of CXCR2. <i>Journal of Hepatology</i> , 2016, 65, 988-997.	3.7	134
52	Increased ratio of neutrophil elastase to antitrypsin is closely associated with liver inflammation in patients with nonalcoholic steatohepatitis. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2016, 43, 13-21.	1.9	34
53	Isocitrate Dehydrogenase 2 Suppresses the Invasion of Hepatocellular Carcinoma Cells via Matrix Metalloproteinase 9. <i>Cellular Physiology and Biochemistry</i> , 2015, 37, 2405-2414.	1.6	19
54	Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease. <i>Liver International</i> , 2015, 35, 2392-2400.	3.9	71

#	ARTICLE	IF	CITATIONS
55	ZJU index: a novel model for predicting nonalcoholic fatty liver disease in a Chinese population. <i>Scientific Reports</i> , 2015, 5, 16494.	3.3	72
56	Randomized, three-arm study to optimize lamivudine efficacy in hepatitis B e antigen-positive chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 748-755.	2.8	26
57	Neutrophils Play a Crucial Role in the Early Stage of Nonalcoholic Steatohepatitis via Neutrophil Elastase in Mice. <i>Cell Biochemistry and Biophysics</i> , 2015, 73, 479-487.	1.8	52
58	The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients: A randomized, controlled study. <i>Hepatology</i> , 2014, 59, 1283-1292.	7.3	69
59	Randomized, Vitamin E-Controlled Trial of Bicyclol Plus Metformin in Non-Alcoholic Fatty Liver Disease Patients with Impaired Fasting Glucose. <i>Clinical Drug Investigation</i> , 2014, 34, 1-7.	2.2	31
60	Toll-like receptor 4 signalling in the progression of nonalcoholic fatty liver disease induced by high-fat and high-fructose diet in mice. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 482-488.	1.9	61
61	Nonalcoholic fatty liver disease (NAFLD) fibrosis score predicts 6.6-year overall mortality of Chinese patients with NAFLD. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014, 41, 643-649.	1.9	27
62	Prognostic performance of a series of model for end-stage liver disease and respective I ¹ scores in patients with hepatitis B acute-on-chronic liver failure. <i>Molecular Medicine Reports</i> , 2014, 9, 1559-1568.	2.4	14
63	Curcumin: A Promising Agent Targeting Cancer Stem Cells. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2014, 14, 787-792.	1.7	44
64	Prediction of significant fibrosis and cirrhosis in hepatitis B e antigen negative patients with chronic hepatitis B using routine parameters. <i>Hepatology Research</i> , 2013, 43, 441-451.	3.4	22
65	Serum hepatitis B surface antigen quantification as a useful assessment for significant fibrosis in hepatitis B e antigen-positive hepatitis B virus carriers. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1746-1755.	2.8	25
66	Guidelines for the diagnosis and management of nonalcoholic fatty liver disease: Update 2010. <i>Journal of Digestive Diseases</i> , 2011, 12, 38-44.	1.5	227
67	Guidelines for the diagnosis and management of alcoholic liver disease: Update 2010. <i>Journal of Digestive Diseases</i> , 2011, 12, 45-50.	1.5	143
68	Prevalence and risk factors of hepatic steatosis and its impact on liver injury in Chinese patients with chronic hepatitis B infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1419-1425.	2.8	86